(177) Female Sexual Dysfunction: Can it be Addressed During Infertility Treatment?

A Schaub,A Dubinskaya,M Pisarska,K Eilber
DOI: https://doi.org/10.1093/jsxmed/qdad060.170
2023-05-01
The Journal of Sexual Medicine
Abstract:Abstract Introduction Female sexual dysfunction (FSD) is a highly prevalent and distressing condition in the general population. Women undergoing fertility treatments are at even higher risk of developing sexual dysfunction due to sexual activity being perceived as an obligation to conceive versus for pleasure, stress of whether the current act of intercourse will result in conception, and a sense of sexual activity as being part of a demanding medical treatment regimen. Objective The purpose of this review is to investigate currently used interventions and/or treatments of FSD in the settings of infertility treatment. Methods We conducted a systematic review on the current approaches to treat FSD while undergoing fertility treatments. PubMed, PMC and Google Scholar were queried, and results were screened using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Inclusion criteria for this review were female subjects undergoing infertility treatment, sexual health was described and measured, interventions were performed or recommended to the subjects with measured outcomes, and the manuscript was written in English between January 2000 to June 2022. Case reports and studies that did not address conditions of interest were excluded from analysis. Results Queries identified 2,341 studies of which title and summary were screened. Fourteen articles met inclusion criteria and underwent full text review. Although multiple studies described an association between infertility and different types of FSD, no study described outcomes for FSD interventions in the infertility setting. Conclusions There is a complete lack of FSD treatment options for infertility patients. Clinicians treating infertility patients should consider discussing FSD and its treatment options in this population. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Abbvie, Coloplast, Sprout Pharmaceuticals.
urology & nephrology
What problem does this paper attempt to address?